We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Eating Red Meat Can Stimulate Cancer Progression

By LabMedica International staff writers
Posted on 04 Dec 2008
Researchers have revealed that a new mechanism for how human consumption of red meat and milk products could contribute to the increased risk of cancerous tumors. More...
Their findings suggest that inflammation resulting from a molecule introduced through consumption of these foods could promote tumor growth.

The lead investigators of the study, Ajit Varki, M.D, a professor of medicine and cellular and molecular medicine from the University of California, San Diego School of Medicine (UCSD; La Jolla, CA, USA) and codirector of the UCSD Glycobiology Research and Training Center, and colleagues studied a nonhuman cellular molecule called N-glycolylneuraminic acid (Neu5Gc). Neu5Gc is a type of glycan, or sugar molecule, that humans do not naturally produce, but that can be incorporated into human tissues as a result of eating red meat. The body then develops anti-Neu5Gc antibodies--an immune response that could potentially lead to chronic inflammation, as first suggested in a 2003 Proceedings of the [U.S.] National Academy of Sciences (PNAS) article authored by Dr. Varki. "We've shown that tumor tissues contain much more Neu5Gc than is usually found in normal human tissues," stated Dr. Varki. "We, therefore, surmised that Neu5Gc must somehow benefit tumors."

It has been long recognized by scientists that chronic inflammation can actually stimulate cancer, Dr. Varki explained. Therefore, the researchers wondered if this was why tumors containing the non-human molecule grew even in the presence of Neu5Gc antibodies. "The paradox of Neu5Gc accumulating in human tumors in the face of circulating antibodies suggested that a low-grade, chronic inflammation actually facilitated the tumor growth, so we set out to study that hypothesis," said coauthor Nissi M.Varki, M.D., UCSD professor of pathology.

Using specially bred mouse models that lacked the Neu5Gc molecule--mimicking humans before the molecule is absorbed into the body through ingesting red meat--the investigators induced tumors containing Neu5Gc, and then administered anti-Neu5Gc antibodies to 50% of the mice. In mice that were given antibodies, inflammation was induced, and the tumors grew more rapidly. In the control mice that were not treated with antibodies, the tumors were less aggressive

Other investigators have previously shown that humans who take nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced risk of cancer. Therefore, the mice with cancerous tumors facilitated by anti-Neu5Gc antibodies were treated with an NSAID. In these animals, the anti-inflammatory treatment blocked the effect of the Neu5Gc antibodies and the tumors were reduced in size.

"Taken together, our data indicate that chronic inflammation results from interaction of Neu5Gc accumulated in our bodies from eating red meat with the antibodies that circulate as an immune response to this non-human molecule--and this may contribute to cancer risk," said Dr. Varki.

Dr. Varki's findings were published online November 11, 2008, in advance of print publication in the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS).

Related Links:
University of California, San Diego School of Medicine




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.